BioPharma, Pharma Merck Drug for Heart and Lung Disorder Wins a First-in-Class FDA Approval By Frank Vinluan
BioPharma, Pharma Merck Neuroscience Acquisition Brings a Startup With Parkinson’s, ALS Programs By Frank Vinluan
BioPharma, Pharma Merck KGaA Puts Up €160M for Drug to Rival DNA Damage Cancer Meds From AstraZeneca, Gilead By Frank Vinluan
BioPharma, Pharma Merck Missed on Seagen, But Comes Back With Potential $22B Daiichi ADC Deal By Frank Vinluan
Artificial Intelligence, BioPharma Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals By Frank Vinluan
Legal, BioPharma Why One Healthcare Lawyer Thinks Merck’s Drug Pricing Lawsuit Defense ‘Makes No Sense’ By Katie Adams
BioPharma, Pharma Merck’s $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform By Frank Vinluan
BioPharma, Pharma Merck Vaccines Pipeline Gets Boost Via Deal for Opko Candidate for Epstein-Barr By Frank Vinluan
BioPharma, Pharma Merck Sees No Future for NGM Bio’s Eye Drugs and Declines Licensing Options By Frank Vinluan
BioPharma, Pharma Merck’s $1.3B Imago Buyout Brings Blood Cancer Drug to Rival BMS, Incyte & GSK By Frank Vinluan
BioPharma, Pharma NGM Bio’s Merck-partnered drug for vision loss disorder flunks Phase 2 test By Frank Vinluan
BioPharma, Top Story, Pharma Merck pays Moderna $250M to share equally in cancer vaccine for melanoma By Frank Vinluan
BioPharma, Pharma Merck HIV drug trials paused by FDA will resume under modified plan By Frank Vinluan
BioPharma, Pharma Merck picks circular path to RNA and commits $250M to biotech startup Orna By Frank Vinluan
BioPharma, Pharma Merck turns to biotech Cerevance to feed neuro pipeline with Alzheimer’s drugs By Frank Vinluan
